期刊
PROSTATE
卷 73, 期 1, 页码 1-10出版社
WILEY-BLACKWELL
DOI: 10.1002/pros.22534
关键词
estrogen receptor; cytochrome P450; aromatase; prostate neoplasm; polymorphism
资金
- National Cancer Institute [R01-CA056678, R01-CA092579, R03-CA137799, P50-CA097186]
- Fred Hutchinson Cancer Research Center
- Intramural Program of the National Human Genome Research Institute
- Prostate Cancer Foundation
BACKGROUND Through mediation of estrogen receptors, estradiol has been shown to have both carcinogenic and anti-carcinogenic effects on the prostate. We performed a population-based casecontrol study to investigate variants in estrogen-related genes ESR1, ESR2, CYP19A1, CYP1A1, and CYP1B1 and the potential association with risk of prostate cancer (PCa). MATERIALS AND METHODS We evaluated PCa risk conferred by 73 single nucleotide polymorphisms in 1,304 incident PCa cases and 1,266 age-matched controls. Analysis included stratification by clinical features and assessment of environmental modifiers. RESULTS There was evidence of altered risk of developing PCa for variants in ESR1, CYP1A1, and CYP1B1, however, only CYP1B1 rs1056836 retained significance after adjustment for multiple comparisons. An association with risk for more aggressive PCa was observed for variants in ESR1, ESR2, and CYP19A1, but none was significant after adjustment for multiple comparisons. There was no effect modification by obesity. CONCLUSIONS Germline genetic variation of these estrogen pathway genes may contribute to risk of PCa. Additional studies to validate these results and examine the functional consequence of validated variants are warranted. Prostate 73: 110, 2013. (c) 2012 Wiley Periodicals, Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据